Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.
about
Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, anIncorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
P2860
Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Busulfan-melphalan in high-ris ...... ience of a single institution.
@en
Busulfan-melphalan in high-ris ...... ience of a single institution.
@nl
type
label
Busulfan-melphalan in high-ris ...... ience of a single institution.
@en
Busulfan-melphalan in high-ris ...... ience of a single institution.
@nl
prefLabel
Busulfan-melphalan in high-ris ...... ience of a single institution.
@en
Busulfan-melphalan in high-ris ...... ience of a single institution.
@nl
P2093
P2860
P356
P1476
Busulfan-melphalan in high-ris ...... ience of a single institution.
@en
P2093
C Pasqualini
D Valteau-Couanet
E Benhamou
M-A Raquin
O Hartmann
P Blanchard
S Proust-Houdemont
P2860
P2888
P304
P356
10.1038/BMT.2016.75
P407
P577
2016-04-04T00:00:00Z